Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy w/ Adenoviral & Yeast-based Vaccines to Induce T-cell Responses in Subjects w/ Advanced, Unresectable & Untransplantable HCC

NCT03563170 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT03563170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03563170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy w/ Adenoviral & Yeast-based Vaccines to Induce T-cell Responses in Subjects w/ Advanced, Unresectable & Untransplantable HCC
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
May 25, 2018
Completion date
August 23, 2019
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma non-resectable, hepatocellular carcinoma recurrent